Last reviewed · How we verify
ESPO
ESPO, marketed by Jiangsu Hansoh Pharmaceutical Co., Ltd., holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current marketed status, providing a steady revenue stream for the company. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | ESPO |
|---|---|
| Also known as | Recombinant Human Erythropoietin Injection |
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis (PHASE3)
- Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |